Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...

George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...

The US Food and Drug Administration’s lead drug regulator George Tidmarsh resigned two days after being placed on ...

Executive accused of making false statements about a drug and soliciting a bribe. Baidu’s Apollo Go hits driverless ride ...

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.1 per share a year ago.

The top drug regulator at the Food and Drug Administration (FDA) resigned Sunday, according to officials, after being accused ...

The Food and Drug Administration’s top drug regulator has resigned after being accused of soliciting a bribe and tanking a company’s stock as part of an alleged revenge plot against a former colleague ...

Dr. George Tidmarsh had been placed on leave Friday after Health and Human Services officials were notified of the issues, a ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts and emails ...

Tidmarsh, who was named as director of the Center for Drug Evaluation and Research (CDER) in July, told ABC in an interview ...

On a per-share basis, the Edmonton, Alberta-based company said it had profit of 23 cents. The biotechnology company posted revenue of $73.5 million in the period, beating Street forecasts. Three ...

FDA CDER Director George Tidmarsh resigns over controversy involving Aurinia Pharma board chair and lupus drug criticism. Read more here.